Dr Reddy’s Laboratories and Cipla have launched palonosetron hydrochloride injection, 0.25 mg (base)/ 5 mL, a therapeutic equivalent generic version of Aloxi (palonosetron hydrochloride) injection approved by the US FDA.

The Aloxi brand and generic had US sales of approximately $446 million MAT for the most recent twelve months ending in January 2018 according to IQVIA.

Dr Reddy’s palonosetron hydrochloride injection is available in a strength of 0.25 mg/5 mL (free base) in a single-dose vial packaged in a carton containing one vial. Aloxi is a registered trademark of Helsinn Healthcare SA.

Cipla USA, Inc.  has launched under applicable agreements with Helsinn Healthcare SA, in response to the at-risk launch by Teva.

Helsinn Healthcare SA currently manufactures and markets Aloxi in the US through its licensee Eisai Inc. and its affiliate Helsinn Therapeutics (US) Inc. Aloxi containing palonosetron hydrochloride injections (Eq. 0.25 mg base/5 ml) is indicated for prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy and for prevention of acute nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy.

Cipla scrip improved by Rs. 5.60 today to Rs. 542.90 on BSE . However, DRL scrip declined by Rs. 12.80 to Rs.2,061.